Gene & Cell Therapy in Retinal Disease – Hope on the Horizon

A New Frontier in Restoring Vision

For many years, patients with inherited retinal diseases or advanced macular degeneration were told there was little that could be done to restore their sight. While treatments such as laser therapy or injections could slow down disease, the damage was often considered irreversible.

Today, however, the landscape is changing. Gene therapy and cell therapy are at the forefront of medical innovation, offering genuine hope that lost vision may one day be restored. With global research moving rapidly and clinical trials expanding into Australia, these treatments are shifting from “experimental” to “emerging reality.”

Associate Professor Simon Skalicky, Melbourne ophthalmologist and leading glaucoma and cataract specialist, explores what these therapies mean for patients, what progress has been made, and what challenges still lie ahead.

What Is Gene Therapy?

Gene therapy aims to correct or replace faulty genes that cause eye disease. Many inherited retinal conditions, such as retinitis pigmentosa, occur because of specific gene mutations that damage the cells of the retina.

The process involves:

• Using a harmless viral “vector” to deliver healthy copies of the gene into retinal cells.

• Restoring or improving the cells’ ability to function normally.

• Potentially halting or even reversing disease progression.

For example, the RPE65 gene therapy (approved in the US and Europe) has already restored functional vision in patients with rare inherited blindness.

What Is Cell Therapy?

Cell therapy involves transplanting new, healthy cells into the retina to replace those lost to disease. This includes:

• Stem cells: which can be coaxed into developing into retinal cells.
  
  

• Retinal pigment epithelium (RPE) cells: grown in laboratories and implanted into the eye.
  
  

• Optogenetics: genetically modifying cells to become light-sensitive, essentially “reprogramming” the eye to see.

The goal is not only to stop progression but to restore visual function where cells have already been damaged.

Conditions That Could Benefit

While still experimental, these therapies are showing promise for:

• Inherited retinal dystrophies (e.g. retinitis pigmentosa, Leber’s congenital amaurosis) - caused by genetic faults that affect the retina’s light-sensing cells, with gene therapy offering potential future treatment.
  
  

• Age-related macular degeneration (AMD) – particularly advanced “dry” AMD, where current treatment options are limited.
  
  

• Diabetic retinopathy – potential for cell therapies to repair damaged retinal tissue.
  
  

• Glaucoma-related optic nerve damage – research is investigating whether cell therapy could regenerate nerve pathways.

For patients in Melbourne and across Australia, these developments could redefine treatment pathways in the next decade.

Recent Global Advances

At the ARVO 2025 ophthalmology conference, researchers presented groundbreaking updates:

• Gene therapies improved night vision and light sensitivity in patients with inherited retinal diseases.
  
  

• Cell-based implants showed safety and early signs of visual improvement in macular degeneration.
  
  

• Clinical trials are expanding to include larger patient groups and longer follow-up periods.

These trials mark an important shift, no longer asking “if” gene and cell therapy will work, but “how well, and for whom.”

Challenges Still Ahead

Despite enormous promise, hurdles remain:

• Cost and access – Current gene therapies overseas can cost hundreds of thousands of dollars.
  
  

• Eligibility – Not all patients with retinal disease have mutations suitable for current treatments.
  
  

• Long-term safety – Researchers are still monitoring whether benefits are sustained over decades.
  
  

• Surgical complexity – Precise delivery of genetic or cell-based material requires highly specialised techniques.

Associate Professor Skalicky explains that while the progress is promising, gene and cell therapy are not yet routine treatments in Australia, and patients may need clinical trial assessment if they wish to explore these options.

Why Australia Is Well-Positioned

Australia has world-class ophthalmology centres and a strong history of pioneering eye research. With experts in genetics, stem cell biology, and clinical trials, Australian patients may soon have access to innovative therapies closer to home.

Importantly, the country’s vast geography and diverse patient populations provide unique opportunities to understand how these treatments perform across different groups.

Integrating With Existing Care

For now, patients with conditions like macular degeneration or glaucoma should continue with evidence-based treatments such as:

• Cataract surgery when vision is clouded.

• Glaucoma therapies such as eye drops, SLT laser, or surgery.

• Injections or laser therapy for macular disease and diabetic retinopathy.

Gene and cell therapy may eventually complement these treatments, but they are not a substitute for timely, proven interventions currently available.

FAQs: Gene & Cell Therapy for Eye Disease

1. Are gene therapies available in Australia now?
Not yet routinely. Some patients may access them through clinical trials or overseas programs.

2. Can gene therapy restore full sight?
Current therapies have shown improvements in functional vision, such as navigating in dim light, but complete restoration is not yet possible.

3. Who is eligible for gene therapy?
Eligibility depends on whether your eye disease is caused by a mutation that can be corrected by existing therapies. Genetic testing is essential.

4. Is cell therapy safe?
Early studies suggest safety, but long-term monitoring is still required to ensure no adverse effects.

5. When might these therapies become mainstream?
Experts predict within the next decade, as more trials conclude and regulatory approvals expand.

Looking Ahead for Patients

Gene and cell therapy are transforming the future of ophthalmology. For patients with inherited retinal diseases or advanced degeneration, these breakthroughs represent genuine hope. While challenges remain around cost, access and long-term outcomes, the direction of research is clear and we are moving closer to a time when restoring sight is possible.

For now, regular eye examinations and timely treatment remain the best way to preserve vision. If you are concerned about retinal disease, glaucoma, or cataracts, book a consultation with Associate Professor Simon Skalicky, one of Melbourne’s leading ophthalmologists. His expertise in both clinical care and research ensures you receive the most up-to-date advice and treatment options.

Learn more at www.drsimonskalicky.com.au